Abstract
In living organisms, homocysteine (Hcy) is a universal intermediate in the metabolic pathways of two other sulfur-containing amino acids: cysteine and methionine. Relative to cysteine, Hcy has in its side chain an extra methylene (βCH2β) group that makes it a higher homolog of cysteine. Compared with methionine, Hcy is missing a methyl (CH3β) group and thus is a lower homolog of methionine. Methionine and cysteine are two canonical coded amino acids that are incorporated by the ribosomal biosynthetic apparatus into polypeptide chains of protein at positions specified by AUG and UGU/UGC codons, respectively. In contrast, Hcy does not normally participate in protein biosynthesis (there is no codon triplet for Hcy) and is considered to be a nonprotein amino acid.
That homocystine itself might be present in proteins is a possibility that should be borne in mind and will be worth investigating
βVincent Du Vigneaud, 1955 Nobel Prize in Chemistry laureate
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Johnson TB. Sulfur linkages in proteins. J Biol Chem. 1911;9:439β48.
Mueller JH. A new sulfur-containing amino acid isolated from the hydrolytic products of protein. J Biol Chem. 1923;58:157β69.
Butz LW, du Vigneaud V. The formation of homologue of cysteine by the decomposition of methionine with sulfuric acid. J Biol Chem. 1932;99:135β42.
Riegel B, Du Vigneaud V. The isolation of homocysteine and its conversion to a thiolactone. J Biol Chem. 1935;112:149β54.
Finkelstein JD. Homocysteine: a history in progress. Nutr Rev. 2000;58(7):193β204.
Jakubowski H. Quality control in tRNA charging. Wiley Interdiscip Rev RNA. 2012;3(3):295β310.
Jakubowski H. Quality control in tRNA chargingβediting of homocysteine. Acta Biochim Pol. 2011;58(2):149β63.
Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31β62.
Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009;60:39β54.
Joseph J, Handy DE, Loscalzo J. Quo vadis: whither homocysteine research? Cardiovasc Toxicol. 2009;9(2):53β63.
Benevenga NJ. Toxicities of methionine and other amino acids. J Agric Food Chem. 1974;22(1):2β9.
Benevenga NJ, Steele RD. Adverse effects of excessive consumption of amino acids. Annu Rev Nutr. 1984;4:157β81.
Harper AE, Benevenga NJ, Wohlhueter RM. Effects of ingestion of disproportionate amounts of amino acids. Physiol Rev. 1970;50(3):428β558.
Dayal S, Lentz SR. Murine models of hyperhomocysteinemia and their vascular phenotypes. Arterioscler Thromb Vasc Biol. 2008;28(9):1596β605.
Matsueda S, Niiyama Y. The effects of excess amino acids on maintenance of pregnancy and fetal growth in rats. J Nutr Sci Vitaminol. 1982;28(5):557β73.
Osborne-Pellegrin MJ, Fau D. Effects of chronic absorption of dietary supplements of methionine and cystine on arterial morphology in the rat. Exp Mol Pathol. 1992;56(1):49β59.
Fau D, Peret J, Hadjiisky P. Effects of ingestion of high protein or excess methionine diets by rats for two years. J Nutr. 1988;118(1):128β33.
Zhou J, Moller J, Danielsen CC, Bentzon J, Ravn HB, Austin RC, et al. Dietary supplementation with methionine and homocysteine promotes early atherosclerosis but not plaque rupture in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21(9):1470β6.
Hill CH, Mecham R, Starcher B. Fibrillin-2 defects impair elastic fiber assembly in a homocysteinemic chick model. J Nutr. 2002;132(8):2143β50.
Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease, vol. 2. 8th ed. New York, NY: Mc Graw-Hill; 2001. p. 2007β56.
Richie Jr JP, Leutzinger Y, Parthasarathy S, Malloy V, Orentreich N, Zimmerman JA. Methionine restriction increases blood glutathione and longevity in F344 rats. FASEB J. 1994;8(15):1302β7.
Sanz A, Caro P, Ayala V, Portero-Otin M, Pamplona R, Barja G. Methionine restriction decreases mitochondrial oxygen radical generation and leak as well as oxidative damage to mitochondrial DNA and proteins. FASEB J. 2006;20(8):1064β73.
Komninou D, Leutzinger Y, Reddy BS, Richie Jr JP. Methionine restriction inhibits colon carcinogenesis. Nutr Cancer. 2006;54(2):202β8.
Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974;291(11):537β43.
Thampi P, Stewart BW, Joseph L, Melnyk SB, Hennings LJ, Nagarajan S. Dietary homocysteine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors expression. Atherosclerosis. 2008;197(2):620β9.
Boers G. Moderate hyperhomocysteinaemia and vascular disease: evidence, relevance and the effect of treatment. Eur J Pediatr. 1998;157 Suppl 2:S127β30.
Krupkova-Meixnerova L, Vesela K, Vitova A, Janosikova B, Andel M, Kozich V. Methionine-loading test: evaluation of adverse effects and safety in an epidemiological study. Clin Nutr. 2002;21(2):151β6.
Cottington EM, LaMantia C, Stabler SP, Allen RH, Tangerman A, Wagner C, et al. Adverse event associated with methionine loading test: a case report. Arterioscler Thromb Vasc Biol. 2002;22(6):1046β50.
Kluijtmans LA, Boers GH, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999;65(1):59β67.
Yap S, Boers GH, Wilcken B, Wilcken DE, Brenton DP, Lee PJ, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21(12):2080β5.
Rosenblatt D, Fenton W. Disorders of transsulfuration. In: Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York, NY: Mc Graw-Hill; 2001. p. 2007β56.
Visy JM, Le Coz P, Chadefaux B, Fressinaud C, Woimant F, Marquet J, et al. Homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency revealed by stroke in adult siblings. Neurology. 1991;41(8):1313β5.
McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111β28.
Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136(6 Suppl):1731Sβ40.
Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337(4):230β6.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325(7374):1202.
Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102(11):1227β32.
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DβAgostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimerβs disease. N Engl J Med. 2002;346(7):476β83.
Daly S, Cotter A, Molloy AE, Scott J. Homocysteine and folic acid: implications for pregnancy. Semin Vasc Med. 2005;5(2):190β200.
Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Drevon CA, Gjessing HK, et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med. 2006;166(1):88β94.
Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007;32(4):561β72.
Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233β41.
Ross R. Atherosclerosisβan inflammatory disease. N Engl J Med. 1999;340(2):115β26.
Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005;3(8):1646β54.
Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107(6):675β83.
Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985;37(1):1β31.
Strauss KA, Morton DH, Puffenberger EG, Hendrickson C, Robinson DL, Wagner C, et al. Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. 2007;91(2):165β75.
Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem. 2003;36(6):431β41.
Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369(9557):208β16.
Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke. 2005;36(11):2404β9.
Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567β77.
Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578β88.
Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876β82.
Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol. 2012;11:512β20.
Ebbing M, Bonaa KH, Arnesen E, Ueland PM, Nordrehaug JE, Rasmussen K, et al. Combined analyses and extended follow-up of two randomized controlled homocysteine-lowering B-vitamin trials. J Intern Med. 2010;268(4):367β82.
Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9):e12244.
de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592β600.
Zhang C, Cai Y, Adachi MT, Oshiro S, Aso T, Kaufman RJ, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem. 2001;276(38):35867β74.
Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, et al. TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the cevelopment of atherosclerosis in hyperhomocysteinemia. J Biol Chem. 2003;278(32):30317β27.
Roybal CN, Yang S, Sun CW, Hurtado D, Vander Jagt DL, Townes TM, et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4. J Biol Chem. 2004;279(15):14844β52.
Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006;291(1β2):119β26.
Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26(3):137β46.
Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. EMBO J. 1991;10(3):593β8.
Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Anal Biochem. 2002;308(1):112β9.
Jakubowski H, Goldman E. Editing of errors in selection of amino acids for protein synthesis. Microbiol Rev. 1992;56(3):412β29.
Tuite NL, Fraser KR, OβByrne CP. Homocysteine toxicity in Escherichia coli is caused by a perturbation of branched-chain amino acid biosynthesis. J Bacteriol. 2005;187(13):4362β71.
Sikora M, Jakubowski H. Homocysteine editing and growth inhibition in Escherichia coli. Microbiology. 2009;155(Pt 6):1858β65.
Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci. 2004;61(4):470β87.
Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006;136(6 Suppl):1741Sβ9.
Jacobsen DW. Homocysteine targeting of plasma proteins in hemodialysis patients. Kidney Int. 2006;69(5):787β9.
Jacobsen DW, Catanescu O, Dibello PM, Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med. 2005;43(10):1076β83.
Glowacki R, Bald E, Jakubowski H. Identification and origin of Nepsilon-homocysteinyl-lysine isopeptide in humans and mice. Amino Acids. 2010;39(5):1563β9.
Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 1997;272(3):1935β42.
Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87(1):45β51.
Jakubowski H. Translational incorporation of S-nitrosohomocysteine into protein. J Biol Chem. 2000;275(29):21813β6.
Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr. 2001;131(11):2983Sβ7.
Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med. 2003;41(11):1462β6.
Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999;13(15):2277β83.
Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J Biol Chem. 2002;277(34):30425β8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
Β© 2013 Springer-Verlag Wien
About this chapter
Cite this chapter
Jakubowski, H. (2013). Introduction. In: Homocysteine in Protein Structure/Function and Human Disease. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1410-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1410-0_1
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1409-4
Online ISBN: 978-3-7091-1410-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)